Northern Cross’s Teva Pharmaceuticals TEVA Stock Holding History

Northern Cross’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$18.5M	Sell	860,538 -21,640,266	-96%	-$502M	6.64%	5
2018 Q2	$547M	Sell	22,500,804 -1,998,421	-8%	-$40.8M	9.66%	5
2018 Q1	$419M	Buy	24,499,225 +2,304,437	+10%	+$45M	6.88%	6
2017 Q4	$421M	Sell	22,194,788 -569,597	-3%	-$8.57M	5.46%	6
2017 Q3	$401M	Buy	22,764,385 +4,968,806	+28%	+$112M	5.16%	6
2017 Q2	$591M	Buy	17,795,579 +2,184,172	+14%	+$67.6M	7.62%	6
2017 Q1	$501M	Buy	+15,611,407	New	+$533M	6.8%	6

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Cross's TEVA Position: Q3 2018 in Review

Northern Cross reduced its Teva Pharmaceuticals (TEVA) stake by 96% in Q3 2018, selling an estimated $502M and leaving 860,538 shares worth $18.5M. The position accounts for 6.64% of the portfolio, ranked #5.

Northern Cross first reported a position in TEVA in Q1 2017 and has held it in 7 quarters since. The position peaked at $591M in Q2 2017. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

Northern Cross held 860,538 shares of Teva Pharmaceuticals worth $18.5M as of Q3 2018.
Northern Cross sold 21,640,266 Teva Pharmaceuticals shares in Q3 2018, an estimated $502M.
Teva Pharmaceuticals made up 6.64% of Northern Cross's portfolio in Q3 2018, its #5 holding.
Northern Cross first reported a position in Teva Pharmaceuticals in Q1 2017 and has held it in 7 quarters since.
Northern Cross's Teva Pharmaceuticals position peaked at $591M in Q2 2017.
556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Northern Cross's 13F filing for Q3 2018, filed 9 Nov 2018.